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ABSTRACT 
Objective: In the present study, we have performed the acute and sub-acute toxicity of a standardized polyherbal formulation (HC9) in Swiss albino 
mice.  
Methods: In acute toxicity study, the mice were orally administered with different doses (1750 and 2000 mg/kg) of HC9 and monitored for 14 d. In 
the sub-acute toxicity study, animals received HC9 extract by oral gavage at the doses of 250, 500 and 1000 mg/kg/day (𝑛𝑛=5/group/sex) for 28 d. 
At the end of the study, the animals were sacrificed and evaluated for effect of HC9 on biochemical, hematological and histopathological parameters. 
Results: HC9 did not produce any adverse effects in biochemical, hematological, urine and histopathological parameters in mice. HC9 did not induce 
any adverse effects in terms of mortality and clinical signs in the acute toxicity study. It was well-tolerated by mice up to 2000 mg/kg/body weight. 
In sub-acute toxicity study, no treatment-related adverse effects were found in the mice upto 1000 mg/kg/day dose. No significant changes were 
observed in biochemical and hematological parameters as well as histopathology of tissues (liver, kidney, spleen, heart, lung, thymus, adrenal gland, 
epididymis and testis/ovary) among mice of either sex. 
Conclusion: Our results showed that HC9 did not induce any acute and sub-acute toxicity in male and female mice, thereby, suggesting its safety for 
future clinical application. 
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INTRODUCTION 
Traditional polyherbal formulations have been used globally from time 
immemorial for the treatment and prevention of many non-
communicable and chronic diseases [1-4]. Recent research focus has 
shifted towards the use of herbal medicines due to their diverse 
biological activities, easy availability, cost effective nature and safe usage 
[5-7]. Polyphenols and flavonoids present in the medicinal plants have 
been shown to possess significant anticancer properties [8-10]. Various 
scientific studies, including ours, have suggested the potential of 
medicinal plants as anti-cancer drug candidates [8-9, 11-14]. 
Herbal medicines are traditionally given in the form of polyherbal 
formulations (PHFs) as each ingredient is supposed to have different 
pharmacological function [15-17]. Since, PHFs have a combination of 
compounds, it may be possible that one compound may either 
potentiate the effect or increase the bioavailability or decrease the 
toxicity of other pharmacologically active compound(s) [15]. PHFs 
are usually prescribed to be taken for a longer period and hence may 
cause adverse effects in the patients, thereby warranting evaluation 
of their efficacy and safety profile [18-19].  
In the present study, we have analyzed the safety of a standardized 
poly herbal formulation (HC9) [20] that we have previously reported 
exhibiting significant antioxidant potential and cytotoxic activity in 
breast cancer cell lines [8]. HC9 is composed of nine medicinal herbs 
that include Picrorhiza kurroa, Cyperus rotundus, Zingiber officinale, 
Cedrus deodara, Tinospora cordifolia, Holarrhena antidysenterica, 
Swertia chirata, Cissampelos pareira and Hemidesmus indicus [8, 20]. 
We have found in vitro as well as in vivo that HC9 exhibited significant 
anticancer activity and immunomodulatory potential (Commu-
nicated). In the present paper, we have performed the acute and sub-
acute oral toxicity of HC9 in both the sexes of Swiss albino mice to 
evaluate its toxicity, safety and tolerability profile. The samples were 
analyzed for hematological, biochemical and histopathological 
parameters. The studies were done according to the Organization for 
Economic Cooperation and Development (OECD) guidelines for testing 
of chemicals. 
MATERIALS AND METHODS 
Plant materials and preparation of ethanolic extract 
The whole/part of plant materials of HC9 were purchased from Shri 
Shailya Medi Pharms (Solapur, Maharashtra, India). All the nine 
plant materials were botanically authenticated and validated and 
voucher specimens were deposited at the Department of Botany, 
Agharkar Research Institute and Herbaria of Medicinal Plant 
Conservation Centre (MPCC), Pune as described previously [8]. The 
dried plant materials were separately ground to powders.  
The formulation was prepared by mixing equal parts (1:1 ratio) of 
each individual plant material of HC9 and subjected to extraction in 
ethanol by soxhlet apparatus as described previously [8]. Briefly, the 
resulting extract was centrifuged at 13000 rpm for 15 min, 
supernatant was filter-sterilized using swiney filter (pore size, 0.45 
µm) and stored in aliquots at-80 °C until use. The filtrate was 
standardized by phyto chemical and HPTLC method [20].  
Animals and maintenance 
Healthy Swiss albino mice, 6-8 w old, of either sex, having body 
weights in the range of 20±3 g were procured from the animal house 
of Bioscience (Pune, Maharashtra, India). They were randomly 
divided into different experimental groups. The animals were 
housed in polypropylene cages at an ambient temperature of 21±3 
°C and 30-70% relative humidity, with a 12:12 h light/dark rhythm. 
Animals were acclimatized to laboratory conditions for at least one 
week prior to the start of the experiment. They were provided with 
commercial food pellets (Nutrivet, Pune) and water ad libitum 
unless stated otherwise. The study was approved by the 
Institutional Ethics Committee (CPCSE Reg. No.258/CPCSE) of the 
Medical College of Bharati Vidyapeeth University, Pune. 
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Acute toxicity study 
The acute toxicity of HC9 was evaluated in female Swiss albino mice 
having body weights in the range of 18-22g. The study was 
performed according to OECD guideline 423. The animals were 
divided into 3 groups, with three animals per group. Group I was 
kept as a vehicle control while Groups II and III served as test 
groups. All the mice were fasted prior to oral gavage with HC9 for 1-
2 h. Individual body weights of animals were taken before dosing. 
HC9 was administered orally at 1750 and 2000 mg/kg doses of body 
weight, whereas the control group received distilled water only. 
Food or water was withheld for 2 h after drug treatment. The 
animals were closely monitored for initial 4 h after the 
administration of HC9 and then daily for 14 d to record any signs of 
toxicity such as tremors, convulsions, salivation, hyperactivity, 
ataxia, diarrhea, lethargy, sleep, coma, mydriasis, piloerection, 
gasping and mortality [21-22]. At the end of the study, all the 
animals were sacrificed to analyze the effect of HC9 on different 
organs of the mice.  
Sub-acute toxicity study 
The sub-acute toxicity study of HC9 was performed in Swiss albino mice 
of either sex having body weights in the range of 18-22 g. All the animals 
were randomly distributed into 6 different groups (Group I-VI) 
comprising ten animals (5 males and 5 females) per group (table 1). The 
sub-acute toxicity study was performed according to OECD guideline 
407. Group I served as a vehicle control and received only distilled water. 
Group III, IV and V received HC9 orally at the doses of 250, 500, 1000 
mg/kg, respectively, daily for 28 d. Group II and VI served as satellite 
control and high dose reversible groups, respectively. Group II received 
only distilled water and Group VI received 1000 mg/kg doses of HC9 
orally for 28 d. The satellite/reversible groups were further observed for 
next 2 w post-treatment for the reversibility, persistence, or delayed 
occurrence of toxic effects of HC9 and were sacrificed on 43 d (table 1). 
Body weight of animals as well as their food and water consumption was 
recorded weekly throughout the study period. The animals were 
observed for signs of toxicity and mortality throughout the experimental 
period. The urine samples and blood samples of all the animals were 
taken prior to necropsy. After sacrificing the animals, different organs 
were collected for histopathological analysis.  
Urine analysis 
During the last week of the study period, urine samples from all the 
animals were collected and their analyse was done to evaluate 
various parameters such as appearance, specific gravity, pH, protein, 
ketone bodies, glucose, nitrite, urobilinogen, leucocytes and occult 
blood. Dx Urine test 10 (Piramal healthcare Limited, Mumbai) 
reagent strips were used for urine analysis. 
Hematological analysis  
The animals were fasted overnight prior to necropsy and blood 
collection [22]. Blood samples were collected from retro-orbital sinus 
puncture technique. Different parameters such as hemoglobin (Hb), 
platelet count (P), lymphocyte count (L), eosinophil count (E), monocyte 
count (M), basophil count (B), packed cell volume (PCV), mean 
corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and 
mean corpuscular hemoglobin concentration (MCHC) were estimated. 
Biochemical analysis 
Biochemical analysis of serum samples was performed to analyze 
various parameters such as serum creatinine (CREA), triglycerides 
(TG), total protein (TP), albumin (ALB), total bilirubin (T-BIL), direct 
bilirubin (D-BIL), total cholesterol (TCHOL), blood urea, glucose, 
sodium (Na), potassium (K), serum glutamate oxalo acetete 
trasaminase (SGOT) and alkaline phosphatase (ALP). 
Histopathological Analysis 
After blood collection, animals were sacrificed and different organs 
such as brain, kidney, adrenal gland, liver, heart, spleen, thymus, 
lungs, testis/uterus, and epididymis/ovaries were collected from 
each mouse to observe histopathological changes in the organs. The 
absolute weight of all the organs was recorded and the relative 
organ weight was calculated as:  
Relative organ weight =
Absolute organ weight (g)
Body weight of mouse on sacrificed day (g)
× 100 
The organs were then fixed in 10% neutral buffered formalin for 18 
h at 4 °C and processed by conventional techniques. Paraffin 
sections were stained with hematoxylin and eosin, following the 
standard laboratory procedures. The stained sections were 
examined under the microscope for any cellular damage or change 
in morphology. 
Statistical analysis 
Data have been presented as mean±S.D. Statistical analysis was 
performed with Sigma Stat 3.5 program (Systat Software, Inc.) by 
using two-way ANOVA with α=0.05. 
RESULTS 
Acute toxicity study 
In the acute toxicity study, female Swiss albino mice were orally 
administrated with two different doses (1750 and 2000 mg/kg) of 
HC9 and monitored for 14 d. The treated mice didn’t exhibit any 
mortality, body weight or behavioral change or toxicity compared to 
the control group. Morphological features such as fur, skin, eyes, and 
nose appeared normal. There was no sign of tremors, convulsion, 
salivation, diarrhea, lethargy or unusual behavior such as self 
mutilation or walking backward and so forth in the treated mice. 
There was no change in gait and posture, reactivity to handling, 
sensory stimuli or change in grip strength in the treatment groups.  
Sub-acute toxicity study 
General behaviour and mortality 
Daily oral administration of HC9 at doses of 250, 500 and 1000 
mg/kg for 28 d did not produce any abnormality and toxicity 
symptoms in mice of either sex (table 1). The treated mice did not 
show any abnormal clinical signs such as tremors, convulsions, 
salivation, hyperactivity, ataxia, diarrhea, lethargy, sleep, coma, 
mydriasis, piloerection and gasping. No mortality was recorded in 
any mice due to HC9 treatment. In high dose reversible/satellite 
group, treated with 1000 mg/kg HC9, there were no post-treatment 
related toxicity symptoms or mortality in any of the mice compared 
to the satellite control. 
Changes in body weight and food consumption 
The male and female mice were observed for changes in body 
weight and food consumption that were recorded weekly during the 
treatment period as given in table 2 and table 3, respectively. No 
significant difference (p>0.05) in body weights of male and female 
groups was recorded between control and HC9 treated groups (table 
2a and b, respectively). There was non-significant difference 
(p>0.05) within the groups compared to their initial body weights. 
 
Table 1: Study design for sub-acute toxicity of HC9 treatment in Swiss albino mice 
Groups HC9 dose (mg/kg/body weight) No. of mice Treatment Days Sacrificed on day 
I (Untreated control) 0 10 28 29 
II (Reversal/satellite control) 0 10 28 43 
III (Low dose treatment) 250 10 28 29 
IV(Inter dose treatment) 500 10 28 29 
V(High dose treatment) 1000 10 28 29 
VI (High dose reversal/satellite) 1000 10 28 43 
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Table 2a: Body weights of male Swiss albino mice treated with HC9 
Weeks Body weight change (g) 
Group I  Group II Group III Group IV Group V Group VI 
0 23.40±02.08 24.40±4.04 25.80±4.72 24.20±3.51 24.00±5.03 24.40±7.02 
1 23.00±2.34 26.20±5.93 25.20±3.11 26.80±4.14 24.20±4.49 24.20±2.77 
2 29.60±2.60 27.20±4.32 25.80±4.60 30.80±4.94 25.20±4.66 24.80±1.82 
3 28.20±4.96 27.40±6.10 25.60±4.03 30.60±5.54 26.20±2.48 23.40±1.67 
4 29.80±7.25 27.80±6.68 26.50±3.10 30.20±6.37 26.20±2.48 24.20±1.64 
5  25.60±6.38    25.40±1.14 
6  27.20±6.64    26.60±1.14 
Values are expressed as mean±standard deviation, n=5. HC9 treated groups showed non-significant differences as compared to the control mice 
(p>0.05). 
 
Table 2b: Body weights of female Swiss albino mice treated with HC9 
Weeks Body weight change (g) 
 Group I Group II Group III Group IV Group V Group VI 
0 22.20±4.08 22.20±3.11 23.00±200 22.80±3.03 24.00±5.14 24.40±5.63 
1 21.80±3.89 22.00±2.64 23.20±1.92 22.8±2.58 23.80±3.56 21.60±2.70 
2 23.80±4.26 22.80±3.70 25.20±1.64 25.2±2.68 23.80±3.42 22.40±2.19 
3 24.40±3.50 22.40±3.13 25.20±0.44 24.00±1.58 23.00±3.80 22.00±2.34 
4 24.80±2.58 22.20±3.34 24.20±1.30 24.4±1.14 22.40±2.50 22.60±3.04 
5  23.40±2.96    24.40±3.20 
6  25.00±2.82    25.80±3.11 
Values are expressed as mean±standard deviation, n=5. HC9 treated groups showed non-significant differences as compared with control mice 
(p>0.05). 
 
There was no significant difference (p>0.05) in the food consumption 
pattern of HC9 treated groups compared to their respective controls 
and also within the groups compared to their initial food consumption 
of either male or female mice (table3a and b, respectively). 
  
Table 3a: Food consumption of the male Swiss albino mice treated with HC9 
Weeks Food consumption (g) 
Group I Group II Group III Group IV Group V Group VI 
1 5.75±0.59 6.24±1.41 6.30±0.78 5.36±0.83 8.07±1.50 6.05±0.69 
2 7.40±0.65 8.50±1.76 6.45±0.96 5.70±0.92 7.41±0.64 6.89±0.46 
3 8.00±0.53 6.52±1.45 6.10±0.96 6.65±1.21 6.55±0.62 8.36±0.60 
4 6.21±1.51 6.62±1.59 7.00±0.71 5.39±1.14 5.95±0.57 6.72±0.46 
5  4.13±1.03    5.77±0.26 
6  4.69±1.75    6.94±1.70 
Values are expressed as mean±standard deviation, n=5. HC9 treated groups showed non-significant differences as compared with control mice 
(p>0.05).  
 
Table 3b: Food consumption of the female Swiss albino mice treated with HC9 
Weeks Food consumption (g) 
Group I Group II Group III Group IV Group V Group VI 
1 6.67±1.59 7.29±1.25 6.41±0.71 6.60±1.04 6.36±1.10 6.09±0.43 
2 6.98±0.92 7.16±0.68 6.89±0.61 7.08±1.71 6.60±1.13 6.71±1.89 
3 7.77±2.29 8.19±1.96 7.45±1.20 7.87±1.21 7.35±1.08 7.18±1.35 
4 5.99±0.88 6.31±0.68 6.24±0.52 6.21±0.53 6.02±1.00 6.10±0.99 
5  4.68±0.59    5.19±0.62 
6  5.00±0.57    5.38±0.65 
Values are expressed as mean±standard deviation, n=5. HC9 treated groups showed non-significant differences as compared with control mice 
(p>0.05). 
 
Urine analysis  
The urinalysis revealed no adverse effects due to HC9 treatment in 
any mice of either sex compared to the vehicle control group in the 
28-day study (Supplementary data S1a-l). The urinalysis parameters 
such as appearance, blood, nitrate, leukocyte, glucose, pH, protein 
and specific gravity did not show any significant differences in HC9 
treated mice of either sex compared to their respective control 
groups. All values were in normal range in control and treatment 
groups of both the sexes (Supplementary data S1a-h). The urinalysis 
of mice under high dose reversible/satellite groups also didn’t 
reveal any significant differences compared to satellite control 
groups of either sex (Supplementary data S1i-l). Thus, the oral 
administration of HC9 did not affect urine parameters in mice.  
Hematological analysis 
HC9 did not induce any abnormal changes in hematological 
parameters such as Hb, MCH, MCHC, PCV, MCV and differential cell 
counts (P, L, M, E, B) in male and female groups compared to their 
respective vehicle controls (table 4a and b, respectively). In male 
groups, all the values, except for eosinophil count (E) of group II 
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(satellite control group), were in the normal range (table 4a). In 
female groups, all the values except for eosinophil count (E) of IV 
group and MCV value in the control group (Group I), were in the 
normal range (table 4b). The slight differences in MCV or 
eosinophil (E) values in control or treated mice of male and female 
groups could be due to some inherent variations in the mice as it 
was not reflected in other groups. Interestingly, the mice under 
high dose reversible/satellite groups didn’t show any significant 
differences in hematological parameters compared to the satellite 
control groups of either sex. These results suggested that 
administration of HC9 in mice did not affect the hematological 
parameters. 
 
Table 4a: Hematological parameters of the male mice treated with HC9 
Parameters# I II III IV V VI Normal range 
Hb (g/dl)  12.53±0.81 13±0.46 12.33±0.68 13.33±0.47 13.4±0.2 12.41±0.46 10.2-16.6 
P (×103/µl) 320.66±6.03 370.66±15.53 390.00±5.00 343.33±5.13 371.66±8.62 400.00±8.00 140-450×103 
L (×103/µl) 61.33±6.66 58.66±8.74 57.33±4.04 61.66±6.11 58.66±8.74 52.23±3.61 55.0-95.0 
E (%) 2.66±0.58 4.33±1.53 2.08±1.00 2.00±1.00 2.33±0.58 2.09±1.00 0.0-3.9 
M (%) 1.33±0.58 2.66±0.58 1.66±0.58 2.45±0.00 1.33±0.58 2.66±1.53 1.0-4.0 
B (%) 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.0-1.0 
PCV (%) 39.7±1.44 40.53±1.80 38.1±2.91 41.2±2.1 40.93±0.85 38.33±1.08 39.0-49.0 
MCV (fl) 53.86±0.55 53.06±2.06 51.46±1.39 53.09±1.23 50.60±0.44 51.43±1.66 45.4-60.3 
MCH (pg) 14.96±0.40 15.16±0.40 14.46±0.42 14.76±0.55 14.43±0.42 15.06±0.21 14.1-19.3 
MCHC (g/dl) 30.13±1.28 30.73±0.74 29.50±1.64 31.43±0.12 31.26±0.57 28.60±0.89 30.2-34.2 
Values are expressed as mean±standard deviation, n=5. HC9 treated groups showed non-significant differences as compared with control mice 
(p>0.05), #Hb: Hemoglobin; P: Platelet counts; L: Lymphocyte count; E: Eosinophil count; M: Monocyte count; B: basinophil count; PCV: packed cell 
volume; MCV: Mean Corpuscular Volume; MCH: Mean Corpuscular Haemoglobin; MCHC: Mean Corpuscular Haemoglobin Concentration 
 
Table 4b: Hematological parameters of the female mice treated with HC9 
Parameters# I II III IV V VI Normal 
range 
Hb (g/dl) 12.80±1.10 12.13±0.87 12.33±0.93 12.27±0.57 12.83±0.93 12.83±0.64 10.2-16.6 
P (×103/µl) 403.00±3.61 405.67±5.03 400.67±3.79 290.00±4.58 390.00±2.65 353.33±3.06 140-450×103 
L (×103/µl) 56.67±3.21 56.33±2.52 56.00±2.65 64.67±4.51 62.67±8.50 55.33±3.79 55.0-95.0 
E (%) 1.67±1.15 3.00±2.00 2.00±1.00 4.67±0.58 3.00±1.00 3.33±0.58 0.0-3.9 
M (%) 1.67±0.58 3.33±0.58 1.33±0.58 1.67±0.87 2.00±1.0 2.67±0.65 1.0-4.0 
B (%) 0.00±0.00 0.00±0.00 0.00±0.0 0.00±0.00 0.00±0.00 0.00±0.00 0.0-1.0 
PCV (%) 41.40±2.36 36.93±2.84 38.47±1.72 38.17±2.71 39.97±2.87 39.23±3.23 39.0-49.0 
MCV (fl) 63.57±17.61 51.03±2.05 52.03±0.12 52.17±0.40 51.90±1.50 52.97±0.57 45.4-60.3 
MCH (pg) 14.90±0.53 14.80±0.95 15.47±0.65 14.77±0.06 15.07±0.68 15.57±0.25 14.1-19.3 
MCHC (g/dl) 30.40±1.42 28.87±2.20 30.30±1.04 30.20±0.26 29.80±1.80 29.77±0.92 30.2-34.2 
Values are expressed as mean±standard deviation, n=5. HC9 treated groups showed non-significant differences as compared with control 
mice (p>0.05), #Hb: Hemoglobin; P: Platelet counts; L: Lymphocyte count; E: Eosinophil count; M: Monocyte count; B: basinophil count; 
PCV: packed cell volume; MCV: Mean Corpuscular Volume; MCH: Mean Corpuscular Haemoglobin; MCHC: Mean Corpuscular Haemoglobin 
Concentration 
 
Biochemical parameters of control and HC9 treated male and female 
groups have been shown in table 5a and 5b, respectively. HC9 did not 
cause any statistically significant changes (p>0.05) in liver and kidney 
function tests such as serum SGOT, SGPT, ALP, CREA, TG, TP, ALB, T-
BIL, D-BIL, TCHOL, blood urea, glucose as well as levels of electrolytes 
such as Na and K in treated groups compared to their respective 
vehicle controls. All the values were within the normal range in both 
the male and female mice (table 5a and 5b, respectively).  
In male control groups, the values of urea, albumin, SGOT and SGPT 
were found to be outside the normal range. However, differences in 
SGPT levels between control group I and groups IV and V; and 
between satellite control group II and group VI (high dose reversible), 
were found to be non-significant (p>0.05) (table 5a). In female control 
groups also, the values of urea, albumin and SGPT were found to be 
outside the normal range. Interestingly, upon HC9 treatment, the 
values of SGPT decreased in treatment groups compared to their 
respective controls (table 5b). SGOT/SGPT ratios, indicative of liver 
function test, were lower in all the treatment groups compared to the 
respective controls in male and female mice (Tables 5c and d, 
respectively). Moreover, serum bilirubin levels were within range in 
HC9 treated male and female mice (tables 5c and d, respectively). 
Organ weights 
The relative organ weights of the mice treated with HC9 have been 
shown in table 6. There was no statistically significant difference 
(p>0.05) found in absolute and relative organ weights of male and 
female mice (Supplementary data S2a and b) and table 6a and b, 
respectively) of the non-reversible and high dose reversible treated 
groups compared to their respective controls. 
Histopathological analysis  
Histopathological examinations of different organs of control and 
HC9 treated mice were done to confirm whether there are any 
alterations in cell structure [23]. At necropsy, no treatment-related 
macroscopic changes were observed in any of the treated mice. The 
analysis of brain, kidney, adrenal gland, liver, heart, spleen, thymus, 
lungs, testis/uterus and epididymis/ovaries of HC9 treated groups 
did not reveal any microscopic changes (Supplementary data S3a 
and b). Some mild cloudy changes observed in kidney sections of 
male and female groups in both control and treatment groups were 
considered to be normal as these were also observed in vehicle 
controls of either sex (Supplementary data S3a and b). Mild swelling 
was observed in one of the mice in high-dose male group (Group V) 
and not in other mice within the same group or other treated 
groups. fig.1a and b show representative histopathological sections 
of heart, kidney, liver, and lung from male and female mice from 
each group, respectively. The treatment with HC9 did not show any 
abnormality in cardiac muscle fibers and glomeruli, tubules and 
interstitium in kidneys. No abnormality was observed in the 
heptatocytes and lungs of the treated animals. The histo-
lopathological pictures of all the vital organs of other mice from 
respective groups were similar (data not shown) to that observed in 
fig.1a and b. 
Ghanekar et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 11, 110-117 
114 
Table 5a: Biochemical findings of the male mice treated with HC9 
Parameters# I II III IV V VI Normal range 
TCHOL (mg/dl) 83.33±17.39 73.00±4.58 73.00±25.12 69.33±10.69 76.00±9.17 70.33±4.04 40.0-130.0 
GLU (mg/dl) 102.67±37.07 144.00±23.58 85.00±17.69 114.00±8.72 80.67±9.45 122.67±43.75 62.0-175.0 
UREA (mmol/l) 42.00±8.19 39.67±5.13 40.00±3.00 38.00±3.0 37.67±3.21 36.67±4.73 8.0-33.0 
CREAT(µmol/l) 0.70±0.11 0.53±0.08 0.62±0.12 0.58±0.06 0.51±0.03 0.47±0.05 0.2-0.9 
TG (mg/dl) 29.00±1.73 37.67±4.04 30.67±17.21 24.67±11.02 30.67±6.11 31.33±6.66 - 
NA (mmol/l) 147.67±6.43 147.67±2.52 153.33±6.43 149.67±1.53 152.67±8.74 148.67±4.51 140.0-160.0 
K (mmol/l) 5.57±0.31 6.17±0.21 5.80±0.30 5.73±0.57 6.03±0.49 5.67±0.25 5.0-7.5 
TP (g/l) 7.17±0.12 7.17±0.38 7.17±0.38 6.83±0.06 6.60±0.61 6.73±0.12 3.5-7.2 
ALB (g/l) 3.57±0.25 3.93±0.15 3.83±0.12 3.60±0.36 3.80±0.44 3.17±0.15 2.5-3.0 
T-BIL (µmol/l) 0.40±0.10 0.47±0.05 0.37±0.06 0.37±0.06 0.40±0.10 0.46±0.10 0.0-0.9 
D-BIL (µmol/l) 0.22±0.01 0.24±0.04 0.23±0.06 0.21±0.02 0.22±0.03 0.23±0.06 <0.3 
SGOT (U/l) 308.33±140.56 305.67±112.59 188.00±8.89 304.67±123.71 270.33±77.73 249.00±88.54 54.0-298.0 
SGPT (U/l) 119.67±9.87 176.67±11.59 114.33±33.72 156.33±22.50 188.33±16.86 210.00±40.29 17.0-77.0 
ALP (U/l) 47.33±13.65 67.67±4.73 70.00±9.85 67.67±16.04 75.00±15.10 62.67±8.50 35.0-96.0 
Values are expressed as mean±standard deviation, n=5. HC9 treated groups showed non-significant differences as compared with control mice 
(p>0.05). #TCHOL: Total Cholesterol; Glu: Glucose; UREA: Blood Urea; CREA: Serum Creatinine; TG: Triglycerides; NA: Sodium; K: Potassium; TP: 
Total Protein; ALB: Albumin; T-BIL: Total Bilirubin; D-BIL: Direct Bilirubin; SGOT: Serum Glutamate Oxaloacetete Trasaminase; SGPT: Serum 
Glutamate Pyruvate Transaminase ALP: Alkaline Phosphatase 
 
Table 5b: Biochemical findings of the female mice treated with HC9 
Parameters# I  II III IV V VI Normal range 
TCHOL (mg/dl) 80.33±11.02 78.67±10.50 64.00±12.77 81.33±16.07 76.33±5.69 83.33±8.74 40.0-130.0 
GLU (mg/dl) 104.33±28.59 114.33±43.66 113.67±43.00 120.67±13.87 96.67±19.50 99.67±13.32 62.0-175.0 
UREA (mmol/l) 40.00±3.61 45.00±5.20 34.67±6.66 39.67±2.52 36.33±3.21 37.67±4.16 8.0-33.0 
CREAT (µmol/l) 0.49±0.03 0.64±0.11 0.64±0.17 0.41±0.03 0.49±0.03 0.43±0.05 0.2-0.9 
TG (mg/dl) 32.33±4.16 35.00±3.61 28.67±7.09 35.67±15.53 33.67±5.03 36.33±5.03 - 
NA (mmol/l) 148.67±4.16 148.00±1.00 150.33±4.16 149.33±3.51 149.00±6.24 154.67±1.53 140.0-160.0 
K (mmol/l) 6.23±0.40 6.00±0.26 5.50±0.26 5.90±0.40 5.90±0.56 6.17±0.25 5.0-7.5 
TP (g/l) 6.20±0.36 7.00±0.10 6.77±0.59 6.83±0.15 6.53±0.40 6.77±0.21 3.5-7.2 
ALB (g/l) 3.33±0.45 3.83±0.12 3.77±0.25 3.57±0.29 3.37±0.40 3.50±0.46 2.5-3.0 
T-BIL (µmol/l) 0.33±0.06 0.44±0.10 0.39±0.19 0.40±0.08 0.36±0.07 0.40±0.04 0.0-0.9 
D-BIL (µmol/l) 0.18±0.09 0.20±0.06 0.21±0.12 0.26±0.05 0.18±0.03 0.22±0.02 <0.3 
SGOT (U/l) 298.07±107.05 195.33±42.52 190.67±11.06 302.00±110.96 244.33±23.09 149.00±28.28 54.0-298.0 
SGPT (U/l) 237.00±86.28 269.33±64.44 151.00±26.91 173.33±4.51 224.67±31.94 166.33±8.33** 17.0-77.0 
ALP (U/l) 64.67±7.77 55.67±24.66 66.00±6.56 71.00±12.12 74.00±0.12 85.67±7.57 35.0-96.0 
Values are expressed as mean±standard deviation, n=5. HC9 treated groups showed non-significant differences as compared with control mice 
(p>0.05). **Significantly different from the control at p<0.01. #TCHOL: Total Cholesterol; Glu: Glucose; UREA: Blood Urea; CREA: Serum Creatinine; 
TG: Triglycerides; NA: Sodium; K: Potassium; TP: Total Protein; ALB: Albumin; T-BIL: Total Bilirubin; D-BIL: Direct Bilirubin; SGOT: Serum 
Glutamate Oxaloacetete Trasaminase; SGPT: Serum Glutamate Pyruvate Transaminase; ALP: Alkaline Phosphatase 
 
 
Fig. 1: Histopathology of different tissues isolated from male and female mice observed under microscope 
 
Histological sections of heart, kidney, liver, and lung isolated from (a) male and (b) female mice from each group have been shown. No obvious 
abnormality in histology was observed in HC9 treated groups at the doses of 250, 500 and 1000 mg/kg compared to the vehicle control groups, as 
seen under the microscope. No post-treatment related histological changes were observed in any of the organ sections of HC9 treated 
reversal/satellite mice compared to the satellite control mice. 
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Table 5c: Liver function test markers of the male mice treated with HC9 
Parameters# I II III IV V VI 
SGOT/SGPT Ratio  2.53±0.92 1.70±0.53 1.74±0.50 2.05±1.08 1.43±0.36 1.17±0.28 
T-BIL (µmol/l) 0.40±0.10 0.47±0.05 0.37±0.06 0.37±0.06 0.40±0.10 0.46±0.10 
D-BIL (µmol/l) 0.22±0.01 0.24±0.04 0.23±0.06 0.21±0.02 0.22±0.03 0.23±0.06 
Values are expressed as mean±standard deviation, n=5. 
 
Table 5d: Liver function test markers of the female mice treated with HC9 
Parameters# I II III IV V VI 
SGOT/SGPT Ratio 1.48±1.07 0.72±0.036 1.28±0.148 1.36±0.308 1.10±0.232 0.85±0.130 
T-BIL (µmol/l) 0.43±0.03 0.44±0.10 0.39±0.19 0.40±0.08 0.36±0.07 0.40±0.04 
D-BIL (µmol/l) 0.27±0.05 0.20±0.06 0.21±0.12 0.26±0.05 0.18±0.03 0.22±0.02 
Values are expressed as mean±standard deviation, n=5. 
 
Table 6a: Relative organ weight of male Swiss albino mice treated with HC9 Relative organ weights of male mice (mg) 
Organs Group I Group II Group III Group IV Group V Group VI 
Brain 1.91±0.19 2.02±0.87 1.56±0.24 1.56±0.37 1.63±0.28 1.59±0.16 
Liver 7.92±0.92 7.32±2.95 6.04±1.20 7.35±2.86 6.47±0.88 5.87±0.32 
Kidney 1.51±0.34 1.56±0.65 1.39±0.41 1.50±0.51 1.46±0.27 1.38±0.14 
Adrenal 0.03±0.01 0.03±0.01 0.02±0.00 0.03±0.01 0.02±0.00 0.02±0.00 
Heart 0.54±0.13 0.64±0.27 0.51±0.06 0.57±0.12 0.57±0.07 0.60±0.10 
Thymus 0.23±0.03 0.20±0.04 0.18±0.01 0.19±0.05 0.19±0.04 0.19±0.04 
Lung 1.11±0.22 1.13±0.34 0.97±0.27 1.08±0.35 0.68±0.19 0.95±0.18 
Spleen 0.57±0.22 0.58±0.12 0.46±0.13 0.46±0.15 0.58±0.19 0.40±0.07 
Testis 0.77±0.23 0.93±0.44 0.72±0.09 0.59±0.09 0.71±0.08 0.88±0.08 
Epididymids 0.27±0.06 0.32±0.12 0.25±0.03 0.28±0.10 0.27±0.10 0.35±0.02 
Values are expressed as mean±standard deviation, n=5. HC9 treated groups showed non-significant differences as compared with control mice 
(p>0.05). 
 
Table 6b: Relative organ weight of female Swiss albino mice treated with HC9 Relative organ weights of female mice (mg) 
Organs Group I Group II Group III Group IV Group V Group VI 
Brain 1.83±0.36 1.64±0.32 1.73±0.06 1.62±0.04 1.83±0.06 1.69±0.13 
Liver 7.16±0.39 5.61±1.01 6.69±0.86 6.71±0.20 6.13±0.61 5.46±0.42 
Kidney 1.20±0.21 1.18±0.26 1.05±0.08 1.15±0.14 1.10±0.12 1.11±0.21 
Adrenal 0.02±0.00 0.02±0.00 0.03±0.01 0.03±0.01 0.03±0.01 0.03±0.01 
Heart 0.55±0.11 0.57±0.09 0.56±0.12 0.53±0.03 0.54±0.09 0.55±0.02 
Thymus 0.30±0.16 0.29±0.07 0.23±0.04 0.27±0.05 0.28±0.04 0.27±0.06 
Lung 1.31±0.10 1.21±0.59 1.23±0.16 1.29±0.26 1.27±0.19 1.18±0.12 
Spleen 0.49±0.12 0.48±0.05 0.45±0.10 0.46±0.05 0.42±0.12 0.49±0.06 
Ovaries 0.08±0.03 0.06±0.01 0.07±0.03 0.09±0.02 0.08±0.00 0.06±0.00 
Uterus 0.33±0.06 0.31±0.07 0.30±0.03 0.25±0.02 0.32±0.05 0.28±0.07 




Herbal medicines have gained increasing global interest due to their 
safety as well as potential to act against various diseases including 
cancer [1-7]. Extensive research is being focused towards the 
traditional and herbal medicines as main sources of chemopreventive 
drugs [8-14]. Many herbal remedies have been reported to possess 
anti-cancer activities and some of them have been used by cancer 
patients for many years [11-14]. However, the safety and toxicity 
assessment of herbal medicines is rarely done before their human 
consumption as they are considered to be inherently safe [7]. The 
clinical use of herbal drugs without adequate scientific evidence has 
raised concerns regarding their toxicity status [24]. Thus, toxicity 
evaluation of herbal medicines is being carried out in various 
experimental animal models to predict their safety and for selecting a 
‘safe’ dose regimen for future human use [23, 25]. 
HC9 is a polyherbal composition of nine medicinal herbs, each one 
reported to have pharmacological action including anticancer, anti-
inflammatory and immunomodulatory activity. We have previously 
reported that HC9 exhibited significant antioxidant potential and 
cytotoxic activity in breast cancer cell lines [8]. Moreover, it also 
exhibited significant anticancer and immunomodulatory activity 
(communicated). We have standardized the formulation with 
respect to its marker compounds [20]. Since, HC9 is effective against 
the breast cancer cell lines, so we wanted to evaluate its toxicity for 
possible therapeutic application. In the present work, the acute and 
subacute toxicity of HC9 was mainly performed to identify a safe 
dose regimen and the therapeutic index of the drug for its possible 
future use. Sub-acute toxicity study is a widely accepted test to 
evaluate any possible health hazards due to treatment with the 
drugs [24, 26]. HC9 didn’t reveal any treatment related adverse 
effects on vital functions of the mice that include cardiovascular, 
central nervous and respiratory systems. Interestingly, 28-day sub-
acute toxicity study did not reveal any adverse effects of HC9 on 
body weights, food consumption, urinalysis, hematology, serum 
biochemistry, gross pathology, organ weights or histopathology.  
HC9 had no gross adverse effect on the hematological parameters in 
mice. The hematological system is an important indicator of the 
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physiological and pathological status of animals or humans [27]. It is 
highly sensitive to toxic compounds and small changes in the 
hematological system could have higher predictive value for drug 
associated toxicity [27]. All the hematological parameters in the 
treatment groups were within the normal range, except for 
eosinophil count (E) of 500 mg/kg treatment group of female mice. 
However, it could be due to some inherent variations in the mice as 
it was not reflected in other groups. Besides, other related 
parameters such as Hb, MCH, MCHC, PCV, MCV, P, L, M and B of the 
mice in the same group were normal. Moreover, the mice under high 
dose reversible/satellite groups didn’t show any significant 
difference in hematological parameters compared to the satellite 
control groups of either sex. Therefore, it could be concluded that 
HC9 was safe for the mice. 
HC9 did not cause any significant change in biochemical parameters 
for hepatic and renal functions such as SGOT, ALP, triglycerides, 
protein, albumin, bilirubin and cholesterol. Clinical biochemistry is 
mainly performed to evaluate the effect of drugs on hepatic and 
renal functions, serum electrolytes as well as glucose and total 
cholesterol levels [28]. Though the values of urea, albumin, SGOT 
and SGPT of control and treated groups were found to be outside the 
normal range, upon HC9 treatment, the values of urea, albumin and 
SGOT were found to decrease in treatment groups compared to their 
respective controls. These results suggest that control mice may 
have some inherent problem with liver function. Hepatic 
biochemical parameters provide valuable information on the status 
of the liver in terms of its functionality, cellular integrity, synthesis 
and its link with biliary tract [29]. Enzymes such as SGOT and ALP 
are well-known indicators of liver function that predict drug related 
toxicity [30]. The ratio of SGOT/SGPT, also known as De Ritis Ratio, 
is an indicative of liver function test (De Ritis F et al., 1957). If the 
ratio is high, it is predictive of liver related complications. Along 
with SGOT/SGPT ratio, serum bilirubin levels are also an important 
indicator of liver function test (Reuben A, 2004). Since, liver is the 
major site of synthesis of cholesterol, protein and albumin as well as 
for cholesterol disposal or degradation, any changes in these 
parameters could be suggestive of liver dysfunction that may be due 
to drug toxicity [30-31]. Our results showed high SGPT levels at 500 
and 1000 mg/kg doses in male mice than the control group. 
However, SGOT/SGPT ratios, were lower in all the treatment groups 
compared to the respective controls in male and female mice (table 
5.7a-b). Interestingly, serum bilirubin levels were within range in 
HC9 treated mice of either sex. Besides the above facts, macroscopic 
observation of organs, organ weights and histological examinations 
of the liver sections together with asymptomatic clinical and 
behavioral signs did not reveal any signs of toxicity upon HC9 
treatment. All together, the data suggested that HC9 did not affect 
the liver function of mice.  
HC9 did not affect the serum levels of blood urea and creatinine in 
any mice of either sex at any dose compared to their respective 
controls. Blood urea and creatinine are important markers of renal 
toxicity [24, 32-34]. There are several reports of kidney toxicity 
related to the use of phytotherapeutic drugs, as kidneys eliminate 
many drugs and their metabolites [29]. Our data showed that HC9 
does not alter the kidney function of mice. 
Organ weight is an important index of physiological and pathological 
status of animals. HC9 didn’t affect the absolute and relative organ 
weights of treated mice of either sex. Histological examinations also 
supported the conclusions from clinical biochemistry studies that 
oral administration of HC9 did not induce any renal or liver damage 
even at higher doses (1000 mg/kg). HC9 did not induce any 
pathological changes in the heart, brain, adrenal gland, thymus, lung, 
spleen and reproductive organs such as testes/uterus and 
epididymes/ovaries of the mice. Thus, the polyherbal formulation, 
HC9, could be considered to be non-toxic and safe for its future 
applications. 
CONCLUSION 
Medicinal plants have played an important role in world health, as 
they are potential sources of new therapeutic agents. Thus, it 
becomes important to evaluate their apparent toxicity. The present 
study showed that HC9, a PHF, didn’t induce any apparent toxicity in 
mice even at higher doses. Thereby, suggesting its possible 
therapeutic application. 
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